Events Archives - Reviopharma

EMA–FDA Joint Q&A on Quality and GMP Aspects of PRIME/Breakthrough Therapy Applications 22-01-2024

Post published:January 22, 2024

The EMA’s PRIority MEdicines (PRIME) scheme and the FDA’s Breakthrough Therapy (BT) designation program are designed to expedite the development of innovative products that address unmet medical needs. However, the…

FDA announces next Cellular, Tissue and Gene Therapies Advisory Committee

Post published:October 3, 2023

Revio is pleased to announce the upcoming 76th Cellular, Tissue, and Gene Therapies Advisory Committee scheduled for October 31, 2023, from 9:00am - 5:00pm ET. Before diving into the agenda…

Revio is a Regulatory Affairs Consultancy – Created to support biopharmaceutical companies and public institutions, working with Advanced Therapy Medicinal Products (ATMPs)